TY - JOUR
T1 - Dose-response effects of marine omega-3 fatty acids on apolipoproteins, apolipoprotein-defined lipoprotein subclasses, and Lp-PLA2 in individuals with moderate hypertriglyceridemia
AU - Skulas-Ray, Ann C.
AU - Alaupovic, Petar
AU - Kris-Etherton, Penny M.
AU - West, Sheila G.
N1 - Publisher Copyright:
© 2015 National Lipid Association.
PY - 2015/5/1
Y1 - 2015/5/1
N2 - Background Apolipoprotein (apo) distribution and lipoprotein (Lp)-associated markers of inflammation, such as lipoprotein-associated phospholipase A2 (Lp-PLA2), influence the atherogenicity of circulating lipids and lipoproteins. Little evidence exists regarding the dose-response effects of the marine omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) on apos, apo-defined Lps, and Lp-PLA2. Objective The purpose of this study was to compare the effects of 0, 0.85, and 3.4 g/d of EPA + DHA on Lp-PLA2 mass and activity in individuals with moderate hypertriglyceridemia. We also measured effects on concentrations of apoAI, apoAII, apoB, apoC, apoD, and apoE-defined Lp subclasses. Methods The study was a randomized, doubleblind, crossover design with 8-week treatment periods and 6-week washout periods. During the 3 treatment periods, subjects (n = 25) received 0 g/d EPA + DHA, 0.85 g/d EPA + DHA (low dose), and 3.4 g/d EPA + DHA (high dose) in random order. Results apoB and apoC-III were significantly decreased by the high dose relative to placebo and low dose (P <.01), as was very low-density lipoprotein cholesterol (P <.005). The low dose had no effect on Lp outcomes compared with placebo. The high- and low-dose effects differed significantly for heparin-precipitated apoC-III, LpB, LpA-I, and apoB/apoA-I ratio (P <.05). There was a trend for a decreased Lp-PLA2 mass with the high dose (P =.1). Conclusion The effects of 3.4 g/d EPA + DHA on apoB and apoC-III may reduce atherosclerotic plaque progression in individuals with elevated triglycerides.
AB - Background Apolipoprotein (apo) distribution and lipoprotein (Lp)-associated markers of inflammation, such as lipoprotein-associated phospholipase A2 (Lp-PLA2), influence the atherogenicity of circulating lipids and lipoproteins. Little evidence exists regarding the dose-response effects of the marine omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) on apos, apo-defined Lps, and Lp-PLA2. Objective The purpose of this study was to compare the effects of 0, 0.85, and 3.4 g/d of EPA + DHA on Lp-PLA2 mass and activity in individuals with moderate hypertriglyceridemia. We also measured effects on concentrations of apoAI, apoAII, apoB, apoC, apoD, and apoE-defined Lp subclasses. Methods The study was a randomized, doubleblind, crossover design with 8-week treatment periods and 6-week washout periods. During the 3 treatment periods, subjects (n = 25) received 0 g/d EPA + DHA, 0.85 g/d EPA + DHA (low dose), and 3.4 g/d EPA + DHA (high dose) in random order. Results apoB and apoC-III were significantly decreased by the high dose relative to placebo and low dose (P <.01), as was very low-density lipoprotein cholesterol (P <.005). The low dose had no effect on Lp outcomes compared with placebo. The high- and low-dose effects differed significantly for heparin-precipitated apoC-III, LpB, LpA-I, and apoB/apoA-I ratio (P <.05). There was a trend for a decreased Lp-PLA2 mass with the high dose (P =.1). Conclusion The effects of 3.4 g/d EPA + DHA on apoB and apoC-III may reduce atherosclerotic plaque progression in individuals with elevated triglycerides.
UR - http://www.scopus.com/inward/record.url?scp=84931562605&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84931562605&partnerID=8YFLogxK
U2 - 10.1016/j.jacl.2014.12.001
DO - 10.1016/j.jacl.2014.12.001
M3 - Article
C2 - 26073395
AN - SCOPUS:84931562605
SN - 1933-2874
VL - 9
SP - 360
EP - 367
JO - Journal of Clinical Lipidology
JF - Journal of Clinical Lipidology
IS - 3
ER -
